Drugs /

pegfilgrastim

Back to Drugs List

Overview

NCI Definition [1]:
A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)

Clinical Trials

View Clinical Trials for pegfilgrastim

Pegfilgrastim has been investigated in 23 clinical trials, of which 19 are open and 4 are closed. Of the trials investigating pegfilgrastim, 3 are phase 1 (2 open), 7 are phase 1/phase 2 (5 open), 10 are phase 2 (9 open), and 3 are phase 3 (3 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for pegfilgrastim clinical trials.

Breast carcinoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia are the most common diseases being investigated in pegfilgrastim clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pegfilgrastim
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pegfilgrastim
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pegfilgrastim and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hsp-130, sd-01, polyethylene glycol-conjugated filgrastim, filgrastim-sd/01, pegfilgrastim (product), pegfilgrastim biosimilar hsp-130, sd-01-filgrastim, pegfilgrastim [chemical/ingredient], pegfilgrastim (substance), neulastim, neulasta, g-csf, filgrastim sd-01, pegfilgrastim, peg sd-01, pegfilgrastim, n-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with .alpha.-methyl-.omega.-hydroxypoly(oxyethylene), sd-01 sustained duration g-csf, gcsf-sd01, sd-01, peg-rmethug-csf, n-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with .alpha.-methyl-.omega.-hydroxypoly(oxyethylene), pluripoietin, n-(3-hydroxypropyl)methionylcolony-stimulating factor (human), 1-ether with alpha-methyl-omega-hydroxypoly(oxyethylene), granulocyte colony-stimulating factor precursor
NCIT ID [1]:
C1854
SNOMED ID [1]:
F-61C35

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.